Squarepoint
ZBIO

Squarepoint’s Zenas BioPharma ZBIO Stock Holding History

Squarepoint’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$838K Buy
42,874
+27,333
+176% +$614K ﹤0.01% 2929
2025
Q4 		$564K Buy
+15,541
New +$511K ﹤0.01% 3107
2024
Q4 		– Sell
-32,299
Closed -$546K – 5588
2024
Q3 		$546K Buy
+32,299
New +$581K ﹤0.01% 3025

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Squarepoint's ZBIO Position: Q1 2026 in Review

Squarepoint increased its Zenas BioPharma (ZBIO) stake by 176% in Q1 2026, buying an estimated $614K and bringing the position to 42,874 shares worth $838K. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

Squarepoint first reported a position in ZBIO in Q3 2024 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Squarepoint held 42,874 shares of Zenas BioPharma worth $838K as of Q1 2026.
  • Squarepoint bought 27,333 Zenas BioPharma shares in Q1 2026, an estimated $614K.
  • Zenas BioPharma made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2929 holding.
  • Squarepoint first reported a position in Zenas BioPharma in Q3 2024 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.